Platinum Industries Limited has announced the successful incorporation of its wholly owned subsidiary, Rivadu Lifesciences Private Limited, marking the company's strategic expansion into the pharmaceuticals and lifesciences sector. The subsidiary received its Certificate of Incorporation from the Ministry of Corporate Affairs on March 18, 2026.

Subsidiary Incorporation Details

Rivadu Lifesciences Private Limited has been incorporated under the provisions of the Companies Act, 2013, with the Corporate Identification Number (CIN) U21000MH2026PTC469557. The incorporation follows the company's earlier intimation to stock exchanges dated February 12, 2026, regarding the planned subsidiary formation.

Financial Structure and Investment

Platinum Industries Limited has made a 100% subscription to the initial paid-up share capital through cash consideration. The investment structure demonstrates the parent company's commitment to establishing a strong foundation for the new venture.

Business Scope and Operations

The newly incorporated subsidiary will operate in the pharmaceuticals and lifesciences sector with a comprehensive business model covering multiple aspects of pharmaceutical operations. Rivadu Lifesciences Private Limited will engage in:

• Manufacturing and Processing: Manufacture, formulation, processing, development, blending, and compounding of pharmaceutical products
• Packaging and Labeling: Packing, repacking, labeling, relabeling, and filling operations
• Commercial Activities: Trading, import, export, stocking, distribution, marketing, sale, and supply of pharmaceutical products

Product Portfolio

The subsidiary's product range will encompass various pharmaceutical categories:

• Active Pharmaceutical Ingredients (APIs)
• Pharmaceutical intermediates
• Excipients and specialty chemicals
• Finished pharmaceutical formulations in multiple dosage forms including:
  • Tablets and capsules
  • Injectables
  • Biologics and biosimilars
  • Vaccines
  • Ophthalmics and dermatologicals
  • Inhalation products and transdermals
  • Nutraceuticals and herbal products

Regulatory Compliance

The incorporation has been completed in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically under Regulation 30. The disclosure follows the requirements outlined in Para A of Part A of Schedule III of SEBI (LODR) Regulations, 2015, along with relevant SEBI circulars dated July 13, 2023, and January 30, 2026.

As a wholly owned subsidiary of Platinum Industries Limited, Rivadu Lifesciences Private Limited is classified as a related party to the holding company. The subsidiary will obtain governmental and regulatory approvals as applicable for its pharmaceutical operations.

Platinum Industries Limited has released the official transcript of its post-earnings conference call held on February 13, 2026, providing detailed insights into the company's Q3FY26 performance and strategic initiatives. The transcript was submitted to stock exchanges on February 18, 2026, under Regulation 30 of SEBI (LODR) Regulations, 2015.

Financial Performance Highlights

The company delivered robust financial performance during Q3FY26, with management highlighting strong growth momentum across both standalone and consolidated operations. Chairman and Managing Director Krishna Rana emphasized the company's leadership position in PVC and CPVC stabilizers manufacturing in India.

Management Commentary on Growth Strategy

During the earnings call, management outlined ambitious growth targets, expecting to accelerate growth trajectory with more than 40% revenue growth in FY2027 and a 35% CAGR from FY2026 to FY2029. CFO Ashok Bothra highlighted that the standalone revenue of ₹102.62 crores represented a 31% year-on-year growth, driven by higher CPVC volumes and improved product mix.

Egypt Facility Development Update

Management provided detailed updates on the Egypt facility, which represents a key growth driver for international expansion. The facility is expected to be commissioned by September 2026, with commercial production targeting December 2026.

Palghar Facility Operational Status

The management confirmed that the CPVC manufacturing at the Palghar facility is operational at 60-65% capacity utilization. The calcium zinc production line faced automation issues but is expected to achieve full commercial production by April 2026.

New Business Ventures

The earnings call revealed details about the newly incorporated Rivadu Lifesciences Private Limited, where Platinum Industries holds 70% equity. Management expects revenue generation from the pharmaceutical business starting FY2027, focusing on nutraceuticals, APIs, and excipients through a contract manufacturing model initially.

Market Outlook and Capacity Utilization

Management expressed optimism about PVC market recovery, noting that prices have reversed upward from mid-January 2026 following China's withdrawal of the 13% rebate policy. The company operates with different product mix utilizations, with flakes form running at 95% capacity in Unit 1, while powder capacity utilization has increased from 10% to 20-30%.

Regulatory Compliance

The earnings call transcript was made available on the company's website at platinumindustriesltd.com in compliance with Regulation 46(2)(oa) of SEBI (LODR) Regulations, 2015. The company maintains its commitment to transparent communication with stakeholders through regular disclosures and investor interactions.